Nu Skin Enterprises (NYSE:NUS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Nu Skin is a premier anti-aging company. The company’s anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system. “
Several other analysts have also commented on NUS. ValuEngine raised shares of Nu Skin Enterprises from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. Citigroup reaffirmed a “buy” rating and issued a $81.00 price objective (up previously from $70.00) on shares of Nu Skin Enterprises in a research report on Tuesday, January 23rd. Pivotal Research reissued a “buy” rating and issued a $90.00 price target on shares of Nu Skin Enterprises in a research report on Friday, February 16th. Stifel Nicolaus boosted their price target on shares of Nu Skin Enterprises from $50.00 to $57.00 and gave the company a “sell” rating in a research report on Friday, February 16th. Finally, Deutsche Bank boosted their price target on shares of Nu Skin Enterprises from $75.00 to $77.00 and gave the company a “buy” rating in a research report on Friday, February 16th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Nu Skin Enterprises presently has a consensus rating of “Hold” and an average price target of $71.29.
Nu Skin Enterprises (NYSE:NUS) last announced its quarterly earnings data on Thursday, February 15th. The company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.19 by $0.01. The business had revenue of $666.20 million for the quarter, compared to analyst estimates of $667.39 million. Nu Skin Enterprises had a net margin of 5.68% and a return on equity of 25.23%. The company’s revenue for the quarter was up 25.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.79 earnings per share. equities analysts forecast that Nu Skin Enterprises will post 3.56 EPS for the current year.
In other news, Chairman Steven Lund sold 42,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $68.11, for a total value of $2,860,620.00. Following the sale, the chairman now owns 4,769 shares of the company’s stock, valued at $324,816.59. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last three months, insiders sold 195,978 shares of company stock worth $13,512,733. Insiders own 5.20% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of NUS. Wolverine Asset Management LLC raised its position in shares of Nu Skin Enterprises by 106.9% in the fourth quarter. Wolverine Asset Management LLC now owns 1,514 shares of the company’s stock valued at $103,000 after purchasing an additional 23,378 shares during the period. Cerebellum GP LLC purchased a new position in Nu Skin Enterprises during the fourth quarter valued at approximately $124,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Nu Skin Enterprises during the third quarter valued at approximately $148,000. Amundi Pioneer Asset Management Inc. purchased a new position in Nu Skin Enterprises during the fourth quarter valued at approximately $192,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Nu Skin Enterprises by 38.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,082 shares of the company’s stock valued at $210,000 after acquiring an additional 858 shares in the last quarter. 76.17% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Nu Skin Enterprises (NUS) Downgraded by Zacks Investment Research” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3227555/nu-skin-enterprises-nus-downgraded-by-zacks-investment-research.html.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.